[IMNP] Immune Pharmaceuticals Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.18 Change: -0 (-0.28%)
Ext. hours: Change: 0 (0%)

chart IMNP

Refresh chart

Strongest Trends Summary For IMNP

IMNP is in the medium-term down -92% in 2 months and down -96% in 4 months. In the long-term down -100% below S&P in 2 years and down -100% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer. Its lead product candidate includes Bertilimumab, a human monoclonal antibody that is under Phase II clinical trial for the treatment of ulcerative colitis, as well as for the treatment of bullous pemphigoid, Crohn's disease, and severe asthma. The company?s product pipeline also comprise AmiKet, a topical analgesic cream for the treatment of peripheral neuropathies that is under Phase III clinical trials; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors, which is under Phase I/II clinical trials. In addition, its preclinical stage product candidate includes anti-ferritin combination gemcitabine-paclitaxel NanomAbs for the treatment of pancreatic and non-small cell lung cancer. Immune Pharmaceuticals, Inc. has strategic partn

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-63.26% ROE-144.78% ROI
Current Ratio0.56 Quick Ratio Long Term Debt/Equity-0.43 Debt Ratio0.49
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-460 K Cash From Investing Activities-50 K Cash From Operating Activities-2.25 M Gross Profit
Net Profit-3.56 M Operating Profit-3.45 M Total Assets35.3 M Total Current Assets4.26 M
Total Current Liabilities7.57 M Total Debt3.09 M Total Liabilities19.87 M Total Revenue
Technical Data
High 52 week0.83 Low 52 week0.02 Last close0.02 Last change0%
RSI30.8 Average true range Beta0.68 Volume4.1 M
Simple moving average 20 days-39.61% Simple moving average 50 days-59.37% Simple moving average 200 days-91.29%
Performance Data
Performance Week-18.92% Performance Month-50% Performance Quart-79.73% Performance Half-92.89%
Performance Year-97.89% Performance Year-to-date-97.37% Volatility daily17.83% Volatility weekly39.88%
Volatility monthly81.72% Volatility yearly283.1% Relative Volume67.16% Average Volume507.38 K
New High New Low

News

2018-12-18 08:30:00 | Immune Pharmaceuticals Engages Extera Partners to Pursue Bertilimumab Strategic Transaction

2018-12-06 09:00:00 | Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders

2018-11-27 07:30:00 | Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights

2018-11-19 17:53:42 | Immune Pharmaceuticals Reschedules Corporate Update Call

2018-11-16 08:30:00 | Immune Pharmaceuticals Schedules Corporate Update Call

2018-10-29 07:50:00 | Report: Developing Opportunities within Strategic Education, Semtech, Immune Pharmaceuticals, American Renal Associates, Thor Industries, and American Woodmark — Future Expectations, Projections Moving into 2018

2018-10-29 07:30:00 | New Clinical Data Support Bertilimumab Activity in Bullous Pemphigoid

2018-10-17 09:00:00 | Immune Pharmaceuticals Announces Positive Preclinical Results in Asthma

2018-10-10 16:30:00 | Immune Pharmaceuticals Announces $5 Million Financing

2018-09-13 07:30:00 | Immune Pharmaceuticals Provides a Corporate Update

2018-09-11 07:30:00 | Bertilimumab Granted Fast Track Designation for the Treatment of Bullous Pemphigoid

2018-09-10 07:00:00 | Immune Pharmaceuticals Issues Statement on Former Chief Executive Officer

2018-08-20 11:34:13 | Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid

2018-08-02 16:05:00 | Immune Pharmaceuticals Postpones Special Meeting of Stockholders

2018-07-30 08:00:00 | Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for Bertilimumab for the Treatment of Bullous Pemphigoid

2018-07-26 09:15:00 | Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018

2018-07-17 08:30:00 | Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split

2018-07-09 07:28:23 | BRIEF-WuXi Biologics, Immune Pharma Announce Development, Manufacturing Agreement For First-In-Class Monoclonal Antibody

2018-07-09 07:00:00 | WuXi Biologics and Immune Pharmaceuticals Announce Late-phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody

2018-07-06 07:55:00 | Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks

2018-06-25 08:25:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Immune Pharmaceuticals, Wells Fargo, Anadarko Petroleum, CTS, REGENXBIO, and TripAdvisor — New Research Emphasizes Economic Growth

2018-06-08 08:30:00 | Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination

2018-06-04 13:14:21 | Breakeven On The Horizon For Immune Pharmaceuticals Inc NASDAQ:IMNP

2018-06-01 07:30:00 | Breakfast Technical Briefing on Johnson & Johnson and Three Other Additional Healthcare Stocks

2018-05-24 15:15:22 | Is Immune Pharmaceuticals Inc NASDAQ:IMNP An Industry Laggard Or Leader?

2018-05-23 08:00:00 | Immune Pharmaceuticals Provides a Pipeline Update

2018-05-15 09:00:00 | Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

2018-05-07 08:30:00 | Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc.

2018-05-07 08:25:00 | Market Trends Toward New Normal in The AES, Immune Pharmaceuticals, Hercules Capital, Zendesk, Chevron, and Cornerstone OnDemand — Emerging Consolidated Expectations, Analyst Ratings

2018-04-10 07:40:00 | Wired News – Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc

2018-04-02 17:20:00 | Immune Pharmaceuticals Announces 2017 Financial Results

2018-03-12 12:46:11 | Interested In Immune Pharmaceuticals Inc NASDAQ:IMNP? Here’s How It Performed Recently

2018-03-12 08:00:00 | Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium

2018-03-05 08:15:00 | Research Report Identifies CarGurus, Peabody Energy, Brighthouse Financial, CPI Card Group, Alcoa, and Immune Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-03-02 13:07:21 | Immune Pharmaceuticals Inc’s NASDAQ:IMNP Profit Outlook

2018-02-27 08:00:00 | Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders

2018-02-20 07:30:00 | Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

2018-02-06 08:00:00 | Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

2018-01-26 08:00:00 | Immune Pharmaceuticals Announces Adjournment of Annual Meeting

2018-01-23 09:00:00 | Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

2018-01-10 11:15:00 | Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

2018-01-06 13:30:30 | What Are The Drivers Of Immune Pharmaceuticals Inc’s NASDAQ:IMNP Risks?

2018-01-04 09:00:00 | Immune Pharmaceuticals to Present at the Biotech ShowcaseTM Annual Conference on January 10, 2018

2017-12-14 14:05:09 | Is Immune Pharmaceuticals Inc’s NASDAQ:IMNP CEO Salary Justified?

2017-12-11 11:00:00 | Immune Pharmaceuticals Appoints John Zhang, MD, Ph.D. as Vice President, Research and Development

2017-12-05 12:35:08 | Does Immune Pharmaceuticals Inc’s IMNP Past Performance Indicate A Stronger Future?

2017-12-04 07:10:00 | Wired News – Pfizer Announced an Agreement to Develop and Commercialize Basilea’s Antifungal CRESEMBA in China and the Asia/ Pacific Region

2017-11-15 08:34:00 | Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

2017-11-04 19:29:11 | Should You Invest In The Healthcare Stock Immune Pharmaceuticals Inc IMNP?

2017-10-31 07:45:00 | Consolidated Research: 2018 Summary Expectations for Columbia Property Trust, Dr Pepper Snapple, Immune Pharmaceuticals, Air Products and Chemicals, Box, and ACADIA Pharma – Fundamental Analysis, Key Performance Indications